pre-IPO PHARMA

COMPANY OVERVIEW

Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Our purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain’s immune system. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.


LOCATION

  • Cambridge, MA, USA

  • THERAPEUTIC AREAS

  • Neurodegenerative Disease
  • Rare Diseases

  • WEBSITE

    https://www.vigilneuro.com/


    CAREER WEBSITE

    https://www.vigilneuro.com/careers


    SOCIAL MEDIA


    INVESTORS

    alexandria-venture-investments atlas-venture hatteras-venture-partners northpond-ventures


    PRESS RELEASES


    Sep 15, 2021

    Vigil Neuroscience Announces First Subject Enrolled in a Natural History Study of Patients with Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)


    Aug 18, 2021

    Vigil Neuroscience Completes $90 million Series B Financing to Advance a Pipeline of Microglia-targeted Medicines to Treat Rare and Common Neurodegenerative Diseases


    Dec 8, 2020

    Vigil Neuroscience Launches with $50 Million in Financing to Develop Microglia-based Therapeutics for Neurodegenerative Diseases


    For More Press Releases


    Google Analytics Alternative